Technology

Aprea Therapeutics

$5.58
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-1.15%) As of 3:33 PM UTC today

Why Robinhood?

You can buy or sell APRE and other stocks, options, and ETFs commission-free!

About APRE

Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wenji Bao in 2002 and is headquartered in Boston, MA. The listed name for APRE is Aprea Therapeutics, Inc. Common stock.

CEO
Christian S. Schade
Employees
—
Headquarters
Boston, Massachusetts
Founded
2002
Market Cap
111.74M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.27M
High Today
$5.77
Low Today
$5.46
Open Price
$5.75
Volume
507.58K
52 Week High
$41.12
52 Week Low
$4.66

Collections

APRE Earnings

-$5.29
-$3.53
-$1.76
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 25, Pre-Market

You May Also Like

AVD
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure